U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

ed to respond to a collection of information unless it displays a valid OMB control number.				
Confirmation Number	6421			
Application Number	10/742,346			
Filing Date	December 19, 2003			
First Named Inventor	Falotico			
Group Art Unit	1615			
Examiner Name	C. Azpuru			
Attorney Docket Number	CRD5062USNP			

U.S. PATENT DOCUMENTS

PTO/SB/08b (04-07)

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's nitials*	Cite No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T^2
IIIIIais	INO.	CAMPBELL, J., et al. "Cell Biology of Smooth Muscle in Culture: Implications for	
		Atherogenesis", Inter. Angio, 6, 1987, pp. 73-79	
		COLBURN, M., et al. "Dose Responsive Suppression of Myointimal Hyperplasia by	
		Dexamethasone", journal of Vascular Surgery, 15:510-518 (1992)	
		FRANKLIN, S., et al. "Pharmacologic Prevention of Restenosis After Coronary Angioplasty: Review of the Randomized Clinical Trials", Coronary Artery Disease, Vol., 4 No. 3, pp. 232-242 (1993)	
		MAK, K., et al. "Clinical Trials to Prevent Restenosis after Percutaneous Coronary Revascularization", Ann. NY Academy of Science, 811 pp. 255-284 (1997)	
		POMPA , J., et al. Clinical Trials of Restenosis After Coronary Angioplasty", Circulation 84(3) p. 1426-1436 (1991)	
		YOKOI, H., et al. "Effectiveness of an Antioxidant in Preventing Restenosis After Percutaneous Transluminal Coronary Angioplasty: The Probucol Angioplasty Restenosis Trial", JACC, 3(4): p. 855-862 (1997)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450tance in completing the form, call 1-800-PTO-9199 and select option 2.